Liminatus Pharma Inc(LIMN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:00 PM ET (Korea 11/7 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -21.48 | Insider Own | 41.73% | Shs Outstand | 1.1M | Perf Week | -9.93% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.8M | Perf Month | -31.17% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 1.37% | Short Float | 5.08% | Perf Quarter | -56.58% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -7.26% | Short Ratio | 0.19 | Perf Half Y | -74.95% |
| Sales | 0.00B | P/B | 9.46 | EPS next 5Y | - | ROA | -471.47% | Short Interest | 0.04M | Perf YTD | -91.67% |
| Book/sh | 0.27 | P/C | 1.13 | EPS past 3/5Y | - -540.05% | ROE | - | 52W High | -98.2% ($141.50) | Perf Year | -96.03% |
| Cash/sh | 2.25 | P/FCF | - | Sales past 3/5Y | - | ROIC | -4165.92% | 52W Low | 5.68% ($2.40) | Perf 3Y | -99.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -107.04% | Gross Margin | - | Volatility(W/M) | 16.03% 10.4% | Perf 5Y | -99.48% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.12 | EPS Q/Q | -698.35% | Profit Margin | - | RSI (14) | 33.6 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.12 | Sales Q/Q | - | SMA20 | -15.08% ($2.99) | Beta | 0.77 | Target Price | - |
| Payout | - | Debt/Eq | 4.8 | Earnings | - | SMA50 | -26.56% ($3.46) | Rel Volume | 0.15 | Prev Close | $2.63 |
| Employees | 1 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -75.16% ($10.23) | Avg Volume(3M) | 0.21M | Price | $2.54 |
| IPO | 2021/5/26 | Option/Short | No/Yes | Trades | 311 | Volume | 31,907 | Change | -3.42% |
🧬 Lymminatus Pharma () is a clinical- and preclinical-stage biopharma company specializing in targeted immuno-oncology, with its core pipeline consisting of a GCC (Guanylyl Cyclase C) vaccine candidate for GCC-expressing gastrointestinal cancers and IBA101, a next-generation CD47-blocking antibody for solid tumors. The company went public on Nasdaq through a SPAC merger and is currently restructuring its capital structure, most recently signing a $30 million equity financing MOU with Capital Trust Group.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 15% of its average volume.
LIMN has weak earning power
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.5%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #555 of 597 in the industry
Based on market cap of $3M.
CVKD#554 Cadrenal Therapeutics Inc $4M PER - LIMN#555 Liminatus Pharma Inc $3M PER - 
TRAW#555 Traws Pharma Inc $3M PER - 
NRSN#557 NeuroSense Therapeutics Ltd $3M PER - 
ADXN#558 Addex Therapeutics Ltd ADR $3M PER - 
FAQ
What kind of company is LIMN?
LIMN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LIMN?
The market cap of LIMN is approximately $3M, ranking 5,685 within its sector.
What is the 52-week high and low for LIMN?
LIMN has recorded a 52-week high of $141.50 and a low of $2.40.
